Boston Scientific has struck a deal to buy medical-device maker Silk Road Medical for about $1.26 billion, adding a technology for stroke prevention to its vascular portfolio.

The Boston Globe Its stock is up 50 percent. Billion-dollar deals for breakfast. How did Boston Scientific get its mojo back? “It’s been a brick by brick, constant improvement, strengthening ...

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Boston Scientific's earnings growth may slow to the low teens, making current P/E multiples hard to justify. See why BSX stock is a Hold.

Boston Scientific developed a system: Set aside 10 percent of revenue for research and development, including to advance already acquired technologies, and devote much of its profits to new deals.

Boston Scientific Q4 revenue rose 22.4% Y/Y to $4.56B, exceeding the $4.424B consensus. Adjusted EPS of $0.70 beat expectations of $0.66. Cardiovascular sales grew 28.8% to $2.94B, with cardiology ...

Medical-products company Boston Scientific reported third-quarter results before market open Last Updated: Oct. 23, 2024 at 7:39 a.m. ET First Published: Oct. 23, 2024 at 6:55 a.m. ET Share ...

Boston Scientific plans to break ground soon on a major expansion in Maple Grove, a project that’s up for $1.66 million in awards from DEED's Job Creation Fund.

Boston Scientific said on Wednesday it has discontinued sales of its heart device in the European Union and will not seek approval in the U.S. and other markets due to increased clinical and ...

Medical devices maker Boston Scientific said on Tuesday it would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million, gaining access to an FDA-cleared ...

Boston Scientific’s revenue climbed 32%, rising from $12.7 billion in 2022 to $16.7 billion in 2024, driven by an increase in total procedures and the introduction of new products such as POLARx ...

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).